Mobile

An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUP...

Update Il y a 5 ans
Reference: EUCTR2005-005595-33

An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary objective: •To demonstrate non-inferiority with respect to the proportion of patients achieving and maintaining testosterone suppression to castrate levels using a degarelix dosing regimen compared to LUPRON DEPOT® during 12 months treatment

Inclusion criteria

  • Prostate cancer

Links